

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Normand E. ALLAIRE

Appl. No.: 10/534,689

Filed: January 23, 2006

For: Absolute Quantitation of Nucleic

Acids by RT-PCR

Confirmation No.: 8249

Art Unit: 1637

Examiner: Joyce Tung

Atty. Docket: 2159.0340001/EKS/DOS

Second Supplemental Information Disclosure Statement

Mail Stop Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Second Supplemental Information Disclosure Statement is a continuation of the numbering in Applicant's First Supplemental Information Disclosure Statement filed on May 15, 2006 in connection with the above-captioned application.


Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicant has listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicant reserves the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

Applicant has checked the appropriate boxes below.

- I. Statement under 37 C.F.R. 1.704(d). Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in 37 C.F.R.
 § 1.56(c) more than thirty days prior to the filing of this information disclosure statement.
- \[
 \textstyle 2. \] Filing under 37 C.F.R. § 1.97(b). This Information Disclosure Statement is being filed within three months of the date of filing of a national application other than a continued prosecution application (CPA), OR within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application, OR before the mailing date of a first Office Action on the merits OR before the mailing of a first Office Action after the filing of a request for continued examination under 37 C.F.R. § 1.114. No statement or fee is required.
- 3. Filing under 37 C.F.R. § 1.97(c). This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection, or Notice of Allowance, or an action that otherwise closes prosecution in the application.
 - a. Statement under 37 C.F.R. § 1.97(e)(1). I hereby state that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).



☐ 5.	The document(s) was/were cited in a search report by a foreign patent office in a
	counterpart foreign application. Submission of an English language version of
	the search report that indicates the degree of relevance found by the foreign office
	is provided in satisfaction of the requirement for a concise explanation of
	relevance. 1138 OG 37, 38.
☐ 6.	A concise explanation of the relevance of the non-English language document(s) appears below in accordance with 37 C.F.R. § 1.98(a)(3).
⊠ 7.	Copies of documents FP1-FP3 and NPL1-NPL2 are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), no copies of U.S. patents and patent application publications cited on the attached IDS Forms are submitted.
8.	Copies of the documents were cited by or submitted to the Office in an IDS that complies with 37 C.F.R. § 1.98(a)-(c) in Application No, filed, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).
9.	It is expected that the examiner will review the prosecution and cited art in the parent application no(s) in accordance with MPEP 2001.06(b), and indicate in the next communication from the office that the art cited in the earlier prosecution history has been reviewed in connection with the present application.
•	It is respectfully requested that the Examiner initial and return a copy of the
	ed IDS Forms, and indicate in the official file wrapper of this patent application
that th	e documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

- 5 -

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Doyle A. Siever

Attorney for Applicant Registration No. 47,088

Date: August 31, 2007

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600 716863_1.DOC

Equivalent of Form PTO/SB/08A (04-07) Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known **Application Number** 10/534,689 January 23, 2006 Filing Date First Named Inventor Normand E. ALLAIRE Art Unit 1637 **Examiner Name** To Be Assigned

(Use as many sheets as necessary)

ubstitute for form 1449/PTO

Attorney Docket Number 2159.0340001/EKS/DOS Sheet of 1

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
imuais	INO.	Number-Kind Code ^{2 (If Known)}	WIWI-DD-1111	Applicant of Cited Document		
	USI	5,476,774	12-19-1995	Wang et al.		
	US2	5,543,509	08-06-1996	Klotman et al.		
	US3	5,770,360	06-23-1998	Kievits et al.		
	US4	,			,"	
	US5					
	US6					
	US7	, , , , , , , , , , , , , , , , , , , ,				
	US8				-	
	US9					
	US10					
	US11					
_	US12					
	US13					
	US14·					
	US15					
	US16					
	US17					
	US18					
	US19					
	US20					

	FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where	
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)			Relevant Passages or Relevant Figures Appear	T ⁶
	FP1	WO 99/42618	08-26-1999	Patel et al.		
	FP2	WO 01/36680 A2	05-25-2001	Eastman et al.		
	FP3	EP 1 055 734 A2	11-29-2000	Yokoyama et al.		
	FP4					
	FP5					
	FP6					
	FP7					
	FP8					
-	FP9					

714621 1.DOC

I	Examiner	Date	
I	Signature	Considered	

English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

Equivalent of Form PTO/SB/08B (04-07) Approved for use through 09/30/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO	Complete if Known		
SECOND SUPPLEMENTAL	Application Number	10/534,689	
	Filing Date	January 23, 2006	
INFORMATION DISCLOSURE	First Named Inventor	Normand E. ALLAIRE	
STATEMENT BY APPLICANT	Art Unit	1637	
(Use as many sheets as necessary)	Examiner Name	To Be Assigned	
Sheet 1 of 1	Attorney Docket Number	2159.0340001/EKS/DOS	

	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*					
NPL1 S. FRONHOFFS et al., A Method for the Rapid Construction of cRNA Standar Curves in Quantitative Real-Time Reverse Transcription Polymerase Chain Reaction, Molecular and Cellular Probes (2002) 16, pgs. 99-110.					
	NPL2	Supplementary European Search Report for European Patent Application No. 03811624.0 - 1222 PCT/US0336522 dated 02.08.07 (4 pages).			
	NPL3				
	NPL4				
	NPL5				
	NPL6		·		
	NPL7	į			
	NPL8				
	NPL9				
	NPL10				

714620 1.DOC

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

*EXAMINER: Initial if reference considered, whether or not citation is in conformatice with MPEP 609. Draw line through citation in the first conformation on considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.